This nonrandomized clinical trial aimed to evaluate the feasibility of the pertuzumab, atezolizumab, docetaxel, and trastuzumab (PATH) combination as a neoadjuvant treatment in patients with ERBB2-positive early breast cancer and whether it warrants continuation to the next phase. This evidence concerns the gene ERBB2 and breast carcinoma.